Oncor Renews Agreement with Mayo Clinic for Cancer Detection Clinical Trials

Strategic Insights -

Oncor, a leading genetic test system developer, has renewed its agreement with the renowned Mayo Clinic Division of Laboratory Genetics to conduct clinical trials for its DNA probes. The trials aim to evaluate the effectiveness of Oncor's probes in detecting and managing various genetic diseases, including cancer. This partnership builds on the success of previous collaborations, including the completion of clinical trials for the Oncor Chronic Myelogenous Leukemia (CML) Mbcr/abl Genetic Test System.

Key Takeaways:

  • Oncor has renewed its agreement with the Mayo Clinic Division of Laboratory Genetics to conduct clinical trials for its DNA probes.
  • The trials will evaluate the effectiveness of Oncor's probes in detecting and managing genetic diseases, including Leukemia/Lymphoma, Bladder and Breast Cancer.
  • The partnership involves Drs. Gordon Dewald and Syed Jalal, experts in cytogenetics, leading the clinical trials.
  • The agreement is a continuation of a successful three-year partnership between Oncor and the Mayo Clinic, resulting in the completion of clinical trials for the Oncor Chronic Myelogenous Leukemia (CML) Mbcr/abl Genetic Test System.
  • Oncor develops, manufactures, and markets genetic test systems and related products for the detection and management of cancer and other genetic diseases.
  • Clinical trials will be conducted at the Mayo Clinic's laboratory, considered a leading institution for cytogenetics operations.
  • The renewed agreement demonstrates Oncor's commitment to collaborating with top medical institutions to advance cancer detection and treatment.

Statistics:

  • 3 years: The duration of the previous partnership between Oncor and the Mayo Clinic.
  • 2: The number of successful clinical trials completed during the previous partnership, including the Oncor Chronic Myelogenous Leukemia (CML) Mbcr/abl Genetic Test System.
  • 4: The number of genetic diseases targeted for clinical trials under the renewed agreement, including Leukemia/Lymphoma, Bladder and Breast Cancer.
  • 301-963-3500: The phone number for Oncor's customer service.
  • 212-661-8030 and 312-266-7800: Phone numbers for the Financial Relations Board, Inc.

Sources:

  • PRNewswire, April 3, 1995
  • Oncor, Inc.
  • Mayo Clinic Division of Laboratory Genetics
  • The Financial Relations Board, Inc.